Axitinib 1/5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 1/5 mg

Reference Brands: Inlyta (US/EU)

Category: Oncology Cancer Care

Axitinib is an anti-cancer medication used in the treatment of kidney cancer.

Product Description:

Axitinib is a potent, selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. Blocking VEGF signalling prevents a tumour building the new blood vessels it needs to grow beyond a few millimetres. Its selectivity is the point of difference: it inhibits VEGF receptors at concentrations well below those affecting other kinases, giving fewer off-target effects than the multi-kinase inhibitors, and it has a short half-life, so toxicity resolves quickly when it is stopped.

It is used for advanced renal cell carcinoma after failure of one prior systemic therapy, and in combination with immune checkpoint inhibitors as first-line treatment — the combination regimens having become standard of care. Dose titration upward is part of its use: patients without hypertension on the starting dose can be escalated, and blood pressure response is a marker of adequate exposure. Hypertension, fatigue, diarrhoea, hand-foot syndrome, hypothyroidism and proteinuria follow from VEGF blockade.

Sourcing notes. Patent position varies by market, with generics in some. Its main use is now in combination with a checkpoint antibody, so demand is tied to the availability of that partner product rather than standing alone.